Metraipolis › archive › dc_f13a57b2fcab

Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of… — Europe PMC PMID:42495454

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42495454
DOI
10.7759/cureus.111322
License (as archived)
solo-consultazione
Archived
2026-10-19T06:49:14.981Z
SHA-256 of the archived text
b235b7d229680ecffdbab3ab2baa09def500114435122874cfb06056b42d3d6f
Stable URL of this page
https://metraipolis.com/documento/dc_f13a57b2fcab

How to cite

Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of… — Europe PMC PMID:42495454 — Europe PMC (en), https://europepmc.org/article/MED/42495454 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f13a57b2fcab (Metraipolis archive dc_f13a57b2fcab, sha256 b235b7d229680ecffdbab3ab2baa09def500114435122874cfb06056b42d3d6f)
BibTeX
@misc{dcf13a57b2fcab,
  title = {Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of… — Europe PMC PMID:42495454},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42495454},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f13a57b2fcab; sha256 b235b7d229680ecffdbab3ab2baa09def500114435122874cfb06056b42d3d6f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42495454. Agents can read the archived copy with the MCP tool read_document.